McDermott Will & Emery Represents Inhibikase Therapeutics in Its Financing of Up to $275 Million
October 29, 2024
October 29, 2024
CHICAGO, Illinois, Oct. 29 -- McDermott Will and Emery, a law firm, issued the following news release:
International law firm McDermott Will & Emery represented Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company, in connection with its $110 million private placement with potential aggregate financing up to $275 million if all warrants are exercised.
Inhibikase develops Abelson Tyrosine Kinase inhibitor therapeutics to m . . .
International law firm McDermott Will & Emery represented Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company, in connection with its $110 million private placement with potential aggregate financing up to $275 million if all warrants are exercised.
Inhibikase develops Abelson Tyrosine Kinase inhibitor therapeutics to m . . .